Comparative Pharmacology
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus ZIPRASIDONE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus ZIPRASIDONE MESYLATE.
DAPIPRAZOLE HYDROCHLORIDE vs ZIPRASIDONE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
Ziprasidone mesylate is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also antagonizes 5-HT1D, 5-HT2C, and alpha1-adrenergic receptors, and inhibits serotonin and norepinephrine reuptake.
5 mg orally once daily, titrated as needed up to 10 mg once daily.
20 mg intramuscularly (IM) as needed, not to exceed 40 mg/day; oral: 20 mg twice daily with food, titrated up to 80 mg twice daily. Maximum: 160 mg/day oral.
None Documented
None Documented
Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment
Terminal elimination half-life is approximately 2.2 hours (range 1.4–3.6 h) for the mesylate salt; clinical context: requires twice-daily dosing.
Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%)
Approximately 20% renal, 80% fecal/biliary. Unchanged drug accounts for <1% of renal excretion.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic